drugset / Trial / NCT03570619
Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
Phase 2
Completed
56 enrolled
University of Michigan Rogel Cancer Center
Memorial Sloan Kettering Cancer Center · collabUniversity of California, San Francisco · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will attempt to determine the efficacy of checkpoint inhibitor immunotherapy with nivolumab and ipilimumab combination therapy followed by nivolumab monotherapy in patients with metastatic prostate cancer and other tumor solid tumor histologies harboring loss of CDK12 function as well as monotherapy nivolumab treatment in patient with metastatic prostate cancer harboring loss of CDK12 function.
Timeline
- Start
- 2018-12-14
- Primary completion
- 2022-12-22
- Completion
- 2024-03-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |